palopegteriparatide (Yorvipath)

following a full submission assessed under the orphan medicine process:

palopegteriparatide (Yorvipath®) is not recommended for use within NHSScotland.

Indication under review: the treatment of adults with chronic hypoparathyroidism.

Evidence from a double-blind, phase III study demonstrated that at 26 weeks, a significantly higher proportion of patients in the palopegteriparatide group achieved the primary composite outcome (evaluating calcium control, independence from conventional therapy and dosing of study medicines) compared with placebo.

The submitting company’s justification of the treatment’s cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust economic analysis to gain acceptance by SMC.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.